Desmopressin as a Therapy for Bedwetting in Children With Sickle Cell Disease

• Status: Terminated
• Trial end date: 2018-10-27
• Target enrollment: 0
• Participant gender: All

Summary

This study assesses if using the medication desmopressin will decrease nightime bedwetting in children with sickle cell disease.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Montefiore Medical Center
• Treatments: Deamino Arginine Vasopressin

Criteria

Inclusion Criteria:

1. Patients with Hemoglobin SS, SC, SB0thal or SB+thal

2. Patients with at least two episodes of primary nocturnal enuresis per week or four episodes over the two weeks prior to enrollment.

3. Patients with secondary enuresis who have been evaluated and cleared by a pediatric urologist as not having other etiologies of enuresis (e.g. overactive detrusor activity, a genitourinary anatomic abnormality)

Exclusion Criteria:

1. Patients with developmental delay or neurologic dysfunction secondary to stroke.

2. Patients with hypertension or underlying renal disease.

3. Patients with genitourinary anatomic abnormalities. Any prior renal ultrasound showing normal genitourinary anatomy is sufficient to clear a patient for the study.

4. Patients with daytime urinary incontinence

5. Patients with glucosuria on urinalysis.

6. Patients with secondary nocturnal enuresis who have not been evaluated by a pediatric urologist to rule out other etiologies of enuresis.

7. Patients who are pregnant.

8. Patients receiving another medicine for nocturnal enuresis (e.g. imipramine).